Search Results - Chunyk, Allison G

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    A first‐in‐human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults

    A first‐in‐human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults by Davies, Rupert, Peng, Stanford L., Lickliter, Jason, McLendon, Kristi, Enstrom, Amanda, Chunyk, Allison G., Blanchfield, Lori, Wang, NingXin, Blair, Tiffany, Thomas, Heather M., Smith, Alina, Dillon, Stacey R.

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  2. 2
    Bispecific Antibodies in the Treatment of Hematologic Malignancies

    Bispecific Antibodies in the Treatment of Hematologic Malignancies by Duell, Johannes, Lammers, Philip E., Djuretic, Ivana, Chunyk, Allison G., Alekar, Shilpa, Jacobs, Ira, Gill, Saar

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune Diseases

    Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune Disea... by Evans, Lawrence S., Lewis, Katherine E., DeMonte, Daniel, Bhandari, Janhavi G., Garrett, Logan B., Kuijper, Joseph L., Ardourel, Daniel, Wolfson, Martin F., Debrot, Susan, Mudri, Sherri, Kleist, Kayla, Griffin, Luana L., Hebb, LuAnne, Sanderson, Russell J., Wang, NingXin, Seaberg, Michelle, Chunyk, Allison G., Yang, Jing, Hong, Youji, Maria, Zahra, Messenheimer, David J., Holland, Pamela M., Peng, Stanford L., Rixon, Mark W., Dillon, Stacey R.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies

    The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies by Nelson, Michelle H, Fritzell, Sara, Miller, Robert, Werchau, Doreen, Van Citters, Danielle, Nilsson, Anneli, Misher, Lynda, Ljung, Lill, Bader, Robert, Deronic, Adnan, Chunyk, Allison G, Schultz, Lena, Varas, Laura A, Rose, Nadia, Håkansson, Maria, Gross, Jane, Furebring, Christina, Pavlik, Peter, Sundstedt, Anette, Veitonmäki, Niina, Ramos, Hilario J, Säll, Anna, Dahlman, Anna, Bienvenue, David, von Schantz, Laura, McMahan, Catherine J, Askmyr, Maria, Hernandez-Hoyos, Gabriela, Ellmark, Peter

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma

    Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma by Panowski, Siler H, Kuo, Tracy C, Zhang, Yi, Chen, Amy, Geng, Tao, Aschenbrenner, Laura, Kamperschroer, Cris, Pascua, Edward, Chen, Wei, Delaria, Kathy, Farias, Santiago, Bateman, Marjorie, Dushin, Russell G, Chin, Sherman M, Van Blarcom, Thomas J, Yeung, Yik Andy, Lindquist, Kevin C, Chunyk, Allison G, Kuang, Bing, Han, Bora, Mirsky, Michael, Pardo, Ingrid, Buetow, Bernard, Martin, Thomas G, Wolf, Jeffrey L, Shelton, David, Rajpal, Arvind, Strop, Pavel, Chaparro-Riggers, Javier, Sasu, Barbra J

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Glomerulonephritides (GN): TH-PO499

    Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Glomer... by Dillon, Stacey R., Harrison, Pille, Lickliter, Jason, Manjarrez, Kristi L., Smith, Alina, Lessig, Mary C., Sanderson, Russell J., Chunyk, Allison G., Lewis, Katherine, Zayed, Hany, Davies, Rupert H., Peng, Stanford

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: